Regencell Bioscience Holdings (RGC) Total Current Liabilities (2020 - 2025)

Regencell Bioscience Holdings' Total Current Liabilities history runs 6 years deep, the most recent figure standing at $1.7 million for Q4 2025.

• Quarterly Total Current Liabilities changed N/A year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (changed N/A YoY) and the FY2025 annual result came in at $663673.0, up 242.85% from the prior year.
• Total Current Liabilities was $1.7 million for Q4 2025 at Regencell Bioscience Holdings, up from $663673.0 in the prior quarter.
• Across five years, Total Current Liabilities topped out at $4.3 million in Q2 2021 and bottomed at $193578.0 in Q2 2024.
• A 5-year average of $1.3 million and a median of $635293.5 in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities tumbled 86.68% — and 2025, when it surged 242.85%.
• Regencell Bioscience Holdings' Total Current Liabilities stood at $4.3 million in 2021, then tumbled by 86.68% to $577764.0 in 2022, then grew by 5.05% to $606914.0 in 2023, then plunged by 68.1% to $193578.0 in 2024, then soared by 760.54% to $1.7 million in 2025.
• Business Quant data shows RGC's Total Current Liabilities at $1.7 million in Q4 2025, $663673.0 in Q2 2025, and $193578.0 in Q2 2024.